



Financial Tear Sheet

Corporate Profile

Blueprint Medicines is developing a new generation of highly selective and potent kinase medicines to improve the lives of patients with genomically defined diseases. The Company's approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Blueprint Medicines is advancing three programs in clinical development for subsets of patients with gastrointestinal stromal tumors, hepatocellular carcinoma and systemic mastocytosis, as well as multiple programs in research and preclinical development. For more information, please visit www.blueprintmedicines.com.

Primary IR Contact

Kristin Hodous

Blueprint Medicines

Phone: 617-714-6674

E-mail:

khodous@blueprintmedicines.com

Stock Information

BPMC (Common Stock)

Exchange	NASDAQ GS (US Dollar)
Price	\$52.23
Change (%)	▲ 2.23 (4.46%)
Volume	605,562
52 Week Low	\$17.35
Market Cap	\$1,950,919,600
Rolling EPS	-2.90
PE Ratio	0

Shares Outstanding 39,018,392

Data as of June 26, 2017 4:00 p.m. ET



Recent Press Releases & Upcoming Events

June 05, 2017

[Blueprint Medicines Announces New Phase 1 Clinical Data for BLU-285 in Advanced Gastrointestinal Stromal Tumors and Plans to Pursue Expedited Development in Patients with a PDGFR \$\alpha\$ D842V Mutation](#)

June 01, 2017

[Blueprint Medicines to Present at Upcoming Investor Conferences in June](#)

May 17, 2017

[Blueprint Medicines to Present New Data from Ongoing Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal Tumors at 2017 ASCO Annual Meeting](#)

There are currently no events scheduled.

SEC Filings

Filing Date	Form
June 23, 2017	8-K
June 23, 2017	4

Corporate Governance

[Jeffrey Albers](#) Chief Executive Officer

June 23, 2017	4	Marion. Dorsch, Ph.D	Chief Scientific Officer
June 23, 2017	4	Anthony Boral, M.D-Ph.D.	Chief Medical Officer
		Kate Haviland	Chief Business Officer
		Christoph Lengauer, Ph.D.	Executive Vice President

Data provided by Nasdaq. Minimum 15 minutes delayed.